Free shipping on all orders over $ 500

Zanubrutinib

Cat. No. M10025
Zanubrutinib Structure
Synonym:

BGB-3111

Size Price Availability Quantity
2mg USD 100  USD100 In stock
5mg USD 150  USD150 In stock
10mg USD 250  USD250 In stock
25mg USD 500  USD500 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Zanubrutinib (BGB-3111) is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). Zanubrutinib (BGB-3111) selectively binds to and inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.

Chemical Information
Molecular Weight 471.55
Formula C27H29N5O3
CAS Number 1691249-45-2
Solubility (25°C) DMSO 90 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Jonathan Wong, et al. Hemasphere. Efficacy of Zanubrutinib in the Treatment of Bing-Neel Syndrome

[2] Yunhang Guo, et al. J Med Chem. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase

[3] Constantine S Tam, et al. Blood. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

[4] Jingjing Wu, et al. J Hematol Oncol. Second-generation inhibitors of Bruton tyrosine kinase

Related BTK Products
TL-925

TL-925 is a potentially first-in-class Bruton's tyrosine kinase (BTK) inhibitor that targets mast cell-mediated ocular inflammation and hypersensitivity and can be used in studies related to dry eye.

JAK3/BTK-IN-6

JAK3/BTK-IN-6 is a potent BTK and JAK3 dual inhibitor, with IC50 values of 0.6 and 0.4 nM, respectively.

NX-2127

NX-2127 is an orally active, potent BTK inhibitor that induces degradation of mutant BTKC481S in cells, as well as inhibits the proliferation of BTKC481S mutant TMD8 cells. In addition, NX-2127 stimulates T cell activation and increases IL-2 production in primary human T cells.

DBt-10

DBt-10 is a potent BTK degrader.

BTK-IN-27

BTK-IN-27 is a BTK inhibitor (IC50: 0.2 nM).

  Catalog
Abmole Inhibitor Catalog




Keywords: Zanubrutinib, BGB-3111 supplier, BTK, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.